Share this Post
WEB EXCLUSIVE The California-based biopharmaceutical company’s expansion to North Hills will add more than 300 jobs to the Raleigh-Durham community.
The company, which worked to develop treatment options for patients suffering from COVID-19 (receiving U.S. Food and Drug Administration approval of the antiviral drug Veklury, aka remdesivir, in October 2020 for the treatment of COVID patients requiring hospitalization), will be moving into three floors of the 330,000-square-foot office tower just a short walk from the new North Hills Innovation District.
“When the Kane Realty team developed plans for the Innovation District, we hoped to attract forward-thinking, innovative companies to North Hills,” says Kane Realty CEO John Kane. “That’s exactly what we found with Gilead Sciences, a revolutionary biopharmaceutical company that is working to improve public health day in and day out. We hope Gilead employees will enjoy the opportunity to work, live, socialize and spend time outdoors at North Hills.”
Beginning in November, Gilead Sciences’ expansion to North Hills will add jobs in fields like human resources, finance and information technology. And all of these employees will be able to enjoy North Hills’ many amenities, from bars and restaurants to apartments and hotels to gathering spaces, venues, shops and other conveniences. Not to mention all the exciting new experiences that will come with the $1 billion new multiphase North Hills Innovation District, which is currently underway.
Adds Bailey Jones, head of acquisitions for Lionstone Investments, “Attracting a tenant like Gilead Sciences to North Hills reinforces Lionstone’s conviction that exceptional mixed-use projects in the best locations have enduring value.”
Share this Post